Conflict of interest statement: Conflicts of Interest: The authors have noconflicts of interest to declare.45. Memo. 2018;11(1):77-79. doi: 10.1007/s12254-018-0385-1. Epub 2018 Feb 16.ESMO 2017-my personal highlights.Kiesewetter B(1), Dediu M(2), Bartsch R(3)(4).Author information: (1)1Department of Medicine I, Clinical Division of Oncology, Medical UniversityVienna, Vienna, Austria.(2)SANADOR Hospital Bucharest, Str. Sevastopol, Nr. 9, Sector 1, 010991Bucharest, Romania.(3)3Department of Medicine I, Clinical Division of Oncology, Medical UniversityVienna, Vienna, Austria.(4)4German Breast Group, Martin-Behaim-Straße 12, Neu Isenburg, Germany.This article is not intended to be a comprehensive review of all highlightspresented at the recent ESMO Annual Meeting, but rather a summary from a personalpoint of view in three very different fields of oncology. Breast cancer and lung cancer are traditionally in the focus of interest, and again, relevant new datawere presented. The third part of this overview is focused on novel treatmentstrategies in malignant lymphoma, a field that is also quickly evolving andtraditionally underrepresented at meetings dealing with solid cancers.DOI: 10.1007/s12254-018-0385-1 PMCID: PMC5862913PMID: 29606982 